RxDoctor Payments DataLook up a doctor →

Harvey Bowles, MD

Internal Medicine · Nashville, TNNPI 1285723718

Payments from drug & device makers

$202,549in general payments, 2019–2025

Across 732 payments — averaging $276.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$83K
  • AstraZeneca$37K
  • Pfizer$26K
  • Novartis$25K
  • Chiesi USA, Inc.$17K
  • Novo Nordisk$3K
  • plus $12K from 39 others

What the payments were for

  • Food & beverage$13,17298%
  • Education$2672%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$202,549 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$78,934
Medicare patients
144
Services billed
707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide78$149,726
OzempicSemaglutide107$141,751
EliquisApixaban72$75,443
JardianceEmpagliflozin43$49,634
BiktarvyBictegrav/Emtricit/Tenofov Ala12$48,284
FarxigaDapagliflozin Propanediol38$46,407
MyrbetriqMirabegron19$23,825
Soliqua 100-33Insulin Glargine/Lixisenatide21$23,636
LinzessLinaclotide13$19,335
EntrestoSacubitril/Valsartan24$17,765
Janumet XrSitagliptin Phos/Metformin Hcl18$15,433
MounjaroTirzepatide12$14,358
GemtesaVibegron13$10,602
Tresiba Flextouch U-200Insulin Degludec13$10,386
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid36$6,838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$3,152$291,477185 claims
PfizerEliquis$25,658$75,44372 claims
Boehringer IngelheimJardiance$374$49,63443 claims
AstraZenecaFarxiga$36,772$46,40738 claims
Astellas Pharma US IncMyrbetriq$607$23,82519 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$463$23,63621 claims
AbbVieLinzess$60$19,33513 claims
NovartisEntresto$24,683$17,76524 claims
MerckJanumet Xr$308$15,43318 claims
Lilly USA, LLCMounjaro$1,004$14,35812 claims
Sumitomo Pharma America, Inc.Gemtesa$171$10,60213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →